Beijing Tongrentang Co Ltd - Asset Resilience Ratio
Beijing Tongrentang Co Ltd (600085) has an Asset Resilience Ratio of 0.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 600085 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2024)
This chart shows how Beijing Tongrentang Co Ltd's Asset Resilience Ratio has changed over time. See Beijing Tongrentang Co Ltd net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Beijing Tongrentang Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beijing Tongrentang Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥160.39 Million | 0.5% |
| Total Liquid Assets | CN¥160.39 Million | 0.50% |
Asset Resilience Insights
- Limited Liquidity: Beijing Tongrentang Co Ltd maintains only 0.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Beijing Tongrentang Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Tongrentang Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Beijing Tongrentang Co Ltd (2001–2024)
The table below shows the annual Asset Resilience Ratio data for Beijing Tongrentang Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CN¥443.82K ≈ $64.95K |
CN¥31.20 Billion ≈ $4.57 Billion |
+0.00pp |
| 2023-12-31 | 0.00% | CN¥370.38K ≈ $54.20K |
CN¥30.09 Billion ≈ $4.40 Billion |
0.00pp |
| 2022-12-31 | 0.00% | CN¥428.58K ≈ $62.72K |
CN¥27.04 Billion ≈ $3.96 Billion |
-0.01pp |
| 2020-12-31 | 0.01% | CN¥1.50 Million ≈ $219.50K |
CN¥21.84 Billion ≈ $3.20 Billion |
-0.16pp |
| 2019-12-31 | 0.17% | CN¥35.18 Million ≈ $5.15 Million |
CN¥20.92 Billion ≈ $3.06 Billion |
+0.06pp |
| 2015-12-31 | 0.10% | CN¥15.00 Million ≈ $2.19 Million |
CN¥14.34 Billion ≈ $2.10 Billion |
-0.09pp |
| 2014-12-31 | 0.19% | CN¥25.00 Million ≈ $3.66 Million |
CN¥12.95 Billion ≈ $1.89 Billion |
+0.19pp |
| 2003-12-31 | 0.01% | CN¥200.00K ≈ $29.27K |
CN¥2.75 Billion ≈ $401.87 Million |
0.00pp |
| 2002-12-31 | 0.01% | CN¥185.44K ≈ $27.14K |
CN¥2.46 Billion ≈ $359.86 Million |
0.00pp |
| 2001-12-31 | 0.01% | CN¥198.73K ≈ $29.08K |
CN¥2.16 Billion ≈ $315.94 Million |
-- |
About Beijing Tongrentang Co Ltd
Beijing Tongrentang Co., Ltd engages in the research, production, distribution, and sale of Chinese patent medicines in China and internationally. It operates through the Company, Science Company, Commerce Company, and Others segments. The company offers various product dosage forms, such as pills, powders, alcoholic preparations, capsules, oral liquids, and dripping pills. Its products are used … Read more